Granulomatosis with Polyangiitis Treatment Market Share: By Drug Type: Steroids, Immunosuppressant, Others; By Route of Administration: Oral, Injectable, Others; By Mode of Purchase: Prescription, Over the Counter; By Gender: Male, Female; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Granulomatosis with Polyangiitis Treatment Market Overview – 8 Major Markets 
    3.1    Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023) 
    3.2    Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032) 
4    Granulomatosis with Polyangiitis Treatment Overview 
    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Granulomatosis with Polyangiitis Treatment Epidemiology Scenario and Forecast – 8 Major Markets
    6.1    8MM Epidemiology Scenario Overview (2017-2032)
        6.1.1    Prevalence, by Country
            6.1.1.1    U.S.
            6.1.1.2    U.K.
            6.1.1.3    EU4
            6.1.1.4    India
            6.1.1.5    Japan
        6.1.2    Mortality, by Country
            6.1.2.1    U.S.
            6.1.2.2    U.K.
            6.1.2.3    EU4
            6.1.2.4    India
            6.1.2.5    Japan
        6.1.3    Treatment seeking rate, by Country 
            6.1.3.1    U.S.
            6.1.3.2    U.K.
            6.1.3.3    EU4
            6.1.3.4    India
            6.1.3.5    Japan
7    Granulomatosis with Polyangiitis Treatment Market Landscape – 8 Major Markets 
    7.1    Granulomatosis with Polyangiitis Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Granulomatosis with Polyangiitis Treatment: Product Landscape
        7.2.1    Analysis by Drug Type
        7.2.2    Analysis by Route of Administration 
8    Granulomatosis with Polyangiitis Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Granulomatosis with Polyangiitis Treatment Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
        10.2.1    Strengths
        10.2.2    Weaknesses
        10.2.3    Opportunities
        10.2.4    Threats
    10.3    PESTEL Analysis
        10.3.1    Political
        10.3.2    Economic
        10.3.3    Social
        10.3.4    Technological
        10.3.5    Legal
        10.3.6    Environment
    10.4    Porter’s Five Forces Model
        10.4.1    Bargaining Power of Suppliers
        10.4.2    Bargaining Power of Buyers
        10.4.3    Threat of New Entrants
        10.4.4    Threat of Substitutes
        10.4.5    Degree of Rivalry
    10.5    Key Demand Indicators 
    10.6    Key Price Indicators
    10.7    Industry Events, Initiatives, and Trends  
    10.8    Value Chain Analysis
11    Granulomatosis with Polyangiitis Treatment Market Segmentation (2017-2032) - 8 Major Markets 
    11.1    Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type 
        11.1.1    Market Overview
        11.1.2    Steroids
            11.1.2.1    Prednisolone
            11.1.2.2    Dexamethasone
            11.1.2.3    Others
        11.1.3    Immunosuppressant
            11.1.3.1    Cyclosporine
            11.1.3.2    Tacrolimus
            11.1.3.3    Sirolimus
            11.1.3.4    Others
        11.1.4    Others
    11.2    Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
        11.2.1    Market Overview
        11.2.2    Oral
        11.2.3    Injectable
        11.2.4    Others
    11.3    Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
        11.3.1    Market Overview
        11.3.2    Prescription
        11.3.3    Over the Counter
    11.4    Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
        11.4.1    Market Overview
        11.4.2    Male
        11.4.3    Female 
    11.5    Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
        11.5.1    Market Overview
        11.5.2    Hospitals
        11.5.3    Specialty Clinics
        11.5.4    Home Healthcare 
        11.5.5    Others
    11.6    Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
        11.6.1    Market Overview
        11.6.2    Hospital Pharmacies
        11.6.3    Retail Pharmacies
        11.6.4    Others
    11.7    Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Region
        11.7.1    Market Overview
        11.7.2    United States
        11.7.3    EU-4 and the United Kingdom
            11.7.3.1    Germany
            11.7.3.2    France
            11.7.3.3    Italy
            11.7.3.4    Spain
            11.7.3.5    United Kingdom
        11.7.4    Japan
        11.7.5    India 
12    United States Granulomatosis with Polyangiitis Treatment Market (2017-2032)
    12.1    United States Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023) 
    12.2    United States Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
    12.3    United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type 
        12.3.1    Market Overview
        12.3.2    Steroids
            12.3.2.1    Prednisolone
            12.3.2.2    Dexamethasone
            12.3.2.3    Others
        12.3.3    Immunosuppressant
            12.3.3.1    Cyclosporine
            12.3.3.2    Tacrolimus
            12.3.3.3    Sirolimus
            12.3.3.4    Others
        12.3.4    Others
    12.4    United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
        12.4.1    Market Overview
        12.4.2    Oral
        12.4.3    Injectable
        12.4.4    Others
    12.5    United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
        12.5.1    Market Overview
        12.5.2    Prescription
        12.5.3    Over the Counter
    12.6    United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
        12.6.1    Market Overview
        12.6.2    Male
        12.6.3    Female 
    12.7    United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
        12.7.1    Market Overview
        12.7.2    Hospitals
        12.7.3    Specialty Clinics
        12.7.4    Home Healthcare 
        12.7.5    Others
    12.8    United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
        12.8.1    Market Overview
        12.8.2    Hospital Pharmacies
        12.8.3    Retail Pharmacies
        12.8.4    Others
13    EU-4 and United  Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032)
    13.1    EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023) 
    13.2    EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
    13.3    EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type 
        13.3.1    Market Overview
        13.3.2    Steroids
            13.3.2.1    Prednisolone
            13.3.2.2    Dexamethasone
        13.3.3    Immunosuppressant
            13.3.3.1    Cyclosporine
            13.3.3.2    Tacrolimus
            13.3.3.3    Sirolimus
        13.3.4    Others
    13.4    EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
        13.4.1    Market Overview
        13.4.2    Oral
        13.4.3    Injectable
        13.4.4    Others
    13.5    EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
        13.5.1    Market Overview
        13.5.2    Prescription
        13.5.3    Over the Counter
    13.6    EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
        13.6.1    Market Overview
        13.6.2    Male
        13.6.3    Female 
    13.7    EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
        13.7.1    Market Overview
        13.7.2    Hospitals
        13.7.3    Specialty Clinics
        13.7.4    Home Healthcare 
        13.7.5    Others
    13.8    EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
        13.8.1    Market Overview
        13.8.2    Hospital Pharmacies
        13.8.3    Retail Pharmacies
        13.8.4    Others
14    Japan Granulomatosis with Polyangiitis Treatment Market
    14.1    Japan Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023) 
    14.2    Japan Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
    14.3    Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type 
        14.3.1    Market Overview
        14.3.2    Steroids
            14.3.2.1    Prednisolone
            14.3.2.2    Dexamethasone
            14.3.2.3    Others
        14.3.3    Immunosuppressant
            14.3.3.1    Cyclosporine
            14.3.3.2    Tacrolimus
            14.3.3.3    Sirolimus
            14.3.3.4    Others
        14.3.4    Others
    14.4    Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
        14.4.1    Market Overview
        14.4.2    Oral
        14.4.3    Injectable
        14.4.4    Others
    14.5    Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
        14.5.1    Market Overview
        14.5.2    Prescription
        14.5.3    Over the Counter
    14.6    Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
        14.6.1    Market Overview
        14.6.2    Male
        14.6.3    Female 
    14.7    Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
        14.7.1    Market Overview
        14.7.2    Hospitals
        14.7.3    Specialty Clinics
        14.7.4    Home Healthcare 
        14.7.5    Others
    14.8    Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
        14.8.1    Market Overview
        14.8.2    Hospital Pharmacies
        14.8.3    Retail Pharmacies
        14.8.4    Others
15    India Granulomatosis with Polyangiitis Treatment Market
    15.1    India Granulomatosis with Polyangiitis Treatment Market (2017-2032) Historical Value (2017-2023) 
    15.2    India Granulomatosis with Polyangiitis Treatment Market (2017-2032) Forecast Value (2024-2032)
    15.3    India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type 
        15.3.1    Market Overview
        15.3.2    Steroids
            15.3.2.1    Prednisolone
            15.3.2.2    Dexamethasone
            15.3.2.3    Others
        15.3.3    Immunosuppressant
            15.3.3.1    Cyclosporine
            15.3.3.2    Tacrolimus
            15.3.3.3    Sirolimus
            15.3.3.4    Others
        15.3.4    Others
    15.4    India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
        15.4.1    Market Overview
        15.4.2    Oral
        15.4.3    Injectable
        15.4.4    Others
    15.5    India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
        15.5.1    Market Overview
        15.5.2    Prescription
        15.5.3    Over the Counter
    15.6    India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
        15.6.1    Market Overview
        15.6.2    Male
        15.6.3    Female 
    15.7    India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
        15.7.1    Market Overview
        15.7.2    Hospitals
        15.7.3    Specialty Clinics
        15.7.4    Home Healthcare 
        15.7.5    Others
    15.8    India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
        15.8.1    Market Overview
        15.8.2    Hospital Pharmacies
        15.8.3    Retail Pharmacies
        15.8.4    Others 
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    Japan PMDA
        16.1.4    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication Year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by Year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Funding and Investment Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier Landscape
    22.1    Market Share by Top 5 Companies
    22.2    Genentech, Inc. (A subsidiary of F. Hoffman-La Roche Ltd) 
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisitions
        22.2.5    Certifications
    22.3    GlaxoSmithKline plc. 
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisitions
        22.3.5    Certifications
    22.4    Teva Pharmaceutical Industries Ltd. 
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisitions
        22.4.5    Certifications
    22.5    Pfizer Inc. 
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisitions
        22.5.5    Certifications
    22.6    Actiza Pharma
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisitions
        22.6.5    Certifications
    22.7    Sun Pharmaceutical Industries Ltd. 
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisitions
        22.7.5    Certifications
    22.8    Janssen Pharmaceutical, Inc.  
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisitions
        22.8.5    Certifications
    22.9    Novartis AG 
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisitions
        22.9.5    Certifications
    22.10    Sanofi
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic Reach and Achievements
        22.10.4    Mergers and Acquisitions
        22.10.5    Certifications
23    Granulomatosis with Polyangiitis Treatment Treatment Drugs - Distribution Model (Additional Insight)
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.